Fig. 1: Pharmacokinetic profile of A166.
From: Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
a A166 concentration–time curve in each dose group. b A166 and Duo-5 concentration–time curves in the 4.8 and 6.0 mg/kg dose groups. The green dotted line indicates the mean Cmax of T-DXd ADC and free payload in the 5.4 mg/kg dose group, and the blue solid line indicates the mean Cmax of T-DM1 ADC and free payload in the 3.6 mg/kg dose group. Error bars indicate standard deviation (SD). Duo-5 = Duostatin-5 (anti-microtubule agent, payload of A166).
